Evidence map›Paper›PMID 33114528›Full record

ArticleJournal of personalized medicine2020

Ethical Considerations about Genomic Medicine Implementation: Lessons Learned from the eMERGE III Study.

Kentaro Inamura

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Kentaro InamuraDivision of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan.ORCID 0000-0001-6444-3861

Funding

Grant for Lung Cancer Research Not applicableJSPS KAKENHI 19K07426Suzuki Foundation for Urological Medicine Not applicableTakeda Science Foundation Not applicableThe Ichiro Kanehara Foundation Not applicableThe Mochida Memorial Foundation for Medical and Pharmaceutical Research Not applicable
6 · The paper itself

Abstract

The development of high-throughput techniques has permitted the accumulation of enormous amounts of genomic information. As increasing numbers of studies aim to utilize individual genomic information for diagnostic, preventive, or therapeutic purposes, Institutional Review Boards (IRBs) have a greater opportunity to review such types of study protocols. An article published in the

Indexed as

biobankbioethicselectronic health recordelectronic medical recordgenetic testingnext-generation sequencingpersonalized medicineprecision medicineresearch ethicsreturn of results

Identifiers

PMID33114528
PMCPMC7712392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.